You are here: Home ยป Archives for Miscellaneous

Meltwater Wins 2026 PRWeek Global Award for “Best PR Software or AI Platform”

SAN FRANCISCO, May 20, 2026 (GLOBE NEWSWIRE) — Meltwater, the global leader in actionable intelligence for PR, Communications and Marketing teams, has been awarded the PRWeek Global Award for Best PR Software or AI Platform, recognizing the company’s leadership in building solutions that turn global media, social and AI signals into actionable intelligence organizations can rely on to make faster, more confident decisions.

The award reflects Meltwater’s continued investment in AI-powered innovations designed to help teams move beyond passive monitoring and toward proactive, intelligence-driven marketing and communications strategies.

Meltwater Helps Teams Move From Monitoring to Strategic Decision-Making

As narratives move increasingly fast across news, social and AI systems, teams are under growing pressure to understand and act on these shifts in real time. The award from PRWeek recognized several of Meltwater’s innovations built to help teams uncover insights faster, reduce manual work, and respond with confidence, including:

  • Mira, Meltwater’s AI-powered teammate, enables users to surface instant insights through a conversational interface simplifying complex workflows such as news briefings, media list building, brand monitoring, competitor analysis, consumer intelligence and more.
  • Explore+, Meltwater’s enterprise-grade intelligence platform, unifies media, social and AI signals together into one clear, trusted view of the brand, helping global organizations identify trends, collaborate across regions, and share trusted insights at scale.
  • GenAI Lens, the industry’s first large language model (LLM) monitoring solution, gives brands visibility into how they are represented across major AI assistants including ChatGPT, Gemini, Claude, and more, helping organizations understand and shape brand perception in AI-generated responses.

As a result, teams using the Meltwater platform – which analyzes 1.3 billion pieces of content every day across news, social and AI signals – reported up to 60% reductions in reporting time, 30–40% faster insight-to-action, and six-figure savings in operational costs, enabling faster decision-making.

“To succeed today, teams need to stay on top of narratives across more channels and formats than ever before,” said John Box, CEO at Meltwater. “At Meltwater, we’re focused on building solutions that turn billions of signals into actionable intelligence that tells you what's happening across every channel, what it means, and what to do next. We’re proud to see that vision recognized by PRWeek.”

PRWeek Recognition Underscores Meltwater’s Leadership in Actionable Intelligence

The PRWeek Global Awards recognize excellence and innovation across the communications industry worldwide. Meltwater was selected in the Best PR Software or AI Platform category for demonstrating ease of use, creativity, measurable impact, and innovation for communications professionals.

To learn more about Meltwater’s unified intelligence platform, visit meltwater.com.

For more information, please contact:
Kelly Costello
Corporate Communications Director
[email protected]

About Meltwater
Meltwater is the global leader in actionable intelligence for PR, Communications, and Marketing teams. By analyzing 1.3 billion pieces of content daily, Meltwater transforms media, social, and AI signals into intelligence that leaders rely on to make faster, more confident decisions. With 27,000 customers worldwide, Meltwater is the intelligence platform global brands trust to stay ahead.
Meltwater: Intelligence you can act on.
Learn more at meltwater.com.


GLOBENEWSWIRE (Distribution ID 9723620)

شركة Al Tamimi & Company تقدم الاستشارات لشركة سلامة بشأن إصدار صكوك قابلة للتحويل إلزاميًا بقيمة 155 مليون درهم إماراتي لتعزيز ملاءتها المالية

دبي، الإمارات العربية المتحدة, May 18, 2026 (GLOBE NEWSWIRE) —

قدمت شركة Al Tamimi & Company ، الشركة القانونية الرائدة في منطقة الشرق الأوسط وشمال أفريقيا، الاستشارات لشركة SALAMA للتأمين الإسلامي العربي ((Islamic Arab Insurance Company ,PJSC بشأن صفقة استراتيجية لتحسين رأس المال، تضمنت إصدارًا خاصًا لصكوك قابلة للتحويل إلزاميًا متوافقة مع الشريعة الإسلامية بقيمة 155 مليون درهم إماراتي.

تجمع هذه الصفقة بين تخفيض رأس المال، يليه إصدار الصكوك القابلة للتحويل إلزاميًا من خلال شركة ذات غرض خاص، وزيادة رأس المال في نهاية المطاف بالتزامن مع تحويل هذه الصكوك إلى أسهم. وقد اكتتب المستثمرون المحترفون في هذه الصكوك اكتتابًا خاصًا. صُممت هذه الصفقة لتعزيز الملاءة المالية لشركة سلامة ودعم استقرارها المالي على المدى الطويل.

… تم تطوير هيكل الصكوك وفقًا لمعايير هيئة المحاسبة والمراجعة للمؤسسات المالية الإسلامية (AAOIFI) واعتماده من قبل مستشار شرعي خارجي، ويتضمن آلية تحويل إلزامية تُمكّن شركة سلامة من تحويل الصكوك واستبدالها فورًا بأسهم بعد الإصدار. نُفذت الصفقة ضمن إطار الاكتتاب الخاص في دولة الإمارات العربية المتحدة، وشملت مشاركة أطراف ذات صلة، مما استلزم تعزيز الحوكمة والحصول على موافقات المساهمين. كما تم الحصول على جميع الموافقات التنظيمية اللازمة المتعلقة بعملية تحسين رأس المال.

قدمت Al Tamimi & Company الاستشارات القانونية الشاملة للصفقة، بما في ذلك هيكلة الصفقة، وصياغة وثائق الصكوك، والتواصل مع المساهمين، والامتثال للوائح التنظيمية، بالإضافة إلى التنسيق مع الجهات التنظيمية المختصة في دولة الإمارات العربية المتحدة.

وقد علق Andrew Tarbuck، الشريك ورئيس قسم الشركات في Al Tamimi & Company، قائلاً:

“تُبرز هذه الصفقة التطور المتنامي لحلول أسواق رأس المال في دولة الإمارات العربية المتحدة، والدور المتزايد للأدوات المالية المتوافقة مع الشريعة الإسلامية في استراتيجيات ترشيد رأس المال. يسرنا أن نكون قد قدمنا ​​الدعم لشركة SALAMA في هذه الصفقة الهامة التي تُعزز وضعها المالي وتدعم نموها المستقبلي.”

قاد فريق شركة Al Tamimi & Company كل من Andrew Tarbuck، Husam Hourani، Rafiq Jaffar، Carla Saliba،Muhammad Mitha، Anand Singh،Haya Al Barqawi ، وAmna Khan. وقد عملت شركة SHUAA Capital PSC كمستشار مالي.

نبذة عن Al Tamimi & Company

تُعدّ Al Tamimi & Company شركة المحاماة الرائدة في تقديم الخدمات القانونية المتكاملة في دولة الإمارات العربية المتحدة ومنطقة الشرق الأوسط وشمال أفريقيا، ولها 17 مكتبًا في 10 دول. منذ عام 1989، نقدم حلولاً قانونية مبتكرة وفعّالة من حيث التكلفة لمواجهة التحديات التجارية المعقدة.

يجمع فريقنا، الذي يضم أكثر من 580 متخصصاً قانونياً، بين الخبرة العميقة والرؤى العملية، ليقدم استشارات تركز على الجانب التجاري وتسهم في نجاح عملائنا. وانطلاقاً من التزامنا بالتنوع والشمول، نوفر بيئة عمل ديناميكية تجذب أفضل الكفاءات وتمكّننا من تحقيق نتائج متميزة في مختلف القطاعات.

للتواصل الإعلامي

Hadi Ayedh
مدير العلاقات العامة والاتصالات
+971505490461
[email protected] 


GLOBENEWSWIRE (Distribution ID 1001182574)

Al Tamimi & Company Advises SALAMA on AED 155 Million Mandatory Convertible Sukuk to Strengthen Solvency Position

DUBAI, United Arab Emirates, May 18, 2026 (GLOBE NEWSWIRE) — Al Tamimi & Company, the leading full-service law firm in the MENA region, has advised Islamic Arab Insurance Company (PJSC) (“SALAMA”) on a strategic capital optimization transaction involving the private issuance of AED 155 million in Sharia-compliant Mandatory Convertible Sukuks (“MCS”).

The transaction combines a capital reduction followed by the issuance of MCS through a special purpose vehicle, and an ultimate capital increase simultaneously with the conversion of MCS into shares. The MCS were privately subscribed by professional investors. The transaction was designed to strengthen SALAMA’s solvency position and support its long-term financial stability.

The sukuk structure, developed in accordance with AAOIFI standards and certified by an external Sharia advisor, features a mandatory conversion mechanism enabling Salama to immediately convert and exchange the MCS into equity following issuance. The transaction was executed under the UAE’s private offering framework and included related party participation, requiring enhanced governance and shareholder approvals. All applicable regulatory approvals were also obtained in relation to the capital optimization transaction.

Al Tamimi & Company advised on all legal aspects of the transaction, including structuring, drafting the sukuk documentation, shareholder communications, and regulatory compliance, as well as coordinating with the relevant UAE regulatory authorities.

Andrew Tarbuck, Partner and Head of Corporate at Al Tamimi & Company, commented:

“This transaction highlights the growing sophistication of capital markets solutions in the UAE and the increasing role of Sharia-compliant instruments in capital optimization strategies. We are pleased to have supported SALAMA on this important transaction, which reinforces its financial position and supports its future growth.”

The Al Tamimi & Company team was led by Andrew Tarbuck, Husam Hourani, Rafiq Jaffar, Carla Saliba, Muhammad Mitha, Anand Singh, Haya Al Barqawi and Amna Khan. SHUAA Capital PSC acted as financial advisor.

About Al Tamimi and Company

Al Tamimi and Company is the leading full-service law firm in the UAE and MENA region, with 17 offices across 10 countries. Since 1989, we have delivered innovative, cost-effective legal solutions to address complex business challenges.

Our team of 580+ legal professionals combine deep expertise with practical insights, offering commercially focused advice that drives client success. With a commitment to diversity and inclusion, we foster a dynamic environment that attracts top talent and empowers us to deliver outstanding results across industries.

Media Contact

Hadi Ayedh
Public Relations and Communications Manager
+971505490461
[email protected] 


GLOBENEWSWIRE (Distribution ID 1001182429)

Countdown Grant Explores How Cells Remove Damaged Mitochondria — Opening New Possibilities Across Parkinson’s, Chronic Disease, Rare Disease, and Aging

ATLANTA, May 15, 2026 (GLOBE NEWSWIRE) — Countdown, a nonprofit accelerating mitochondrial science and medicine across the full spectrum of human health, announced a new research grant awarded to Dr. Elias Adriaenssens at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria. 

The funding will support a groundbreaking project titled From Hypoxia to Therapy: Unlocking Mitochondrial Clearance Pathways for Disease Treatment, focused on understanding how cells identify, clear, and renew damaged mitochondria, the tiny structures responsible for producing the energy every cell in the body needs to survive and function. 

Mitochondrial dysfunction is a foundational and shared driver across many of today’s most pressing health challenges, from rare and chronic disease to neurodegeneration, metabolic disease, and age-related decline. Yet despite mitochondria’s central role in human health, many of the underlying cellular quality-control mechanisms remain poorly understood. 

One of the most promising emerging areas in mitochondrial medicine is hypoxia therapy, the controlled reduction of oxygen exposure to activate protective cellular pathways. Hypoxia has emerged as a potential therapeutic strategy across a broad range of conditions and diseases, including primary mitochondrial diseases, Parkinson’s, ischemic injury, and age-related decline. Yet despite its therapeutic promise, chronic systemic hypoxia is difficult to implement clinically, requiring prolonged exposure to tightly controlled low-oxygen environments that are not realistically compatible with everyday life. Moreover, systemic hypoxia can induce widespread stress responses and undesirable biological adaptations across multiple tissues.

Dr. Adriaenssens’ research seeks to solve one of the field’s most important challenges: how to isolate the beneficial mitochondrial effects of hypoxia without exposing patients to its dangerous systemic consequences. Every cell has a built-in system for removing damaged mitochondria and maintaining cellular health. When that process breaks down, damaged mitochondria can accumulate inside cells, triggering inflammation, dysfunction, and tissue damage throughout the body. 

The project focuses on a poorly understood mitochondrial quality-control pathway, which appears to act as a brake on the cell’s mitochondrial renewal system. The research aims to identify how to selectively activate protective mitochondrial clearance pathways associated with hypoxia, without triggering the dangerous systemic effects of whole-body hypoxia. 

The long-term goal is to help lay the foundation for therapies that could mimic the protective effects of hypoxia through patient-compatible treatments, eliminating  the impractical and potentially dangerous need for continuous low-oxygen exposure or hypoxic chambers. 

What makes this research especially significant is that cells contain multiple pathways for removing damaged mitochondria, yet science has only deeply understood one of them. By uncovering alternative mitochondrial clearance mechanisms, this research could open new therapeutic possibilities across a wide range of diseases and conditions where mitochondrial dysfunction plays a central role.

The findings may also help advance one of medicine’s most promising emerging frontiers: mitochondrial transplantation. While early studies suggest transplanted mitochondria could help rescue damaged tissues, one of the biggest barriers remains that healthy mitochondria are often recognized and destroyed by the cell before they can successfully integrate and function. Understanding these newly identified quality-control pathways may help overcome that challenge and make mitochondrial transplantation more durable and effective. 

“Countdown funds research at a cellular level, the shared biology beneath conditions that most organizations address in isolation,” said Mitzi Solomon, Founder and President of Countdown. “This grant exemplifies the broad-reaching implications of mitochondrial research, as the molecular insight Dr. Adriaenssens is pursuing could ultimately benefit patients across rare disease, neurodegeneration, heart disease, transplantation, and aging — all at once.” 

“For patients with mitochondrial dysfunction, the options today are still largely supportive. This research moves us toward something genuinely different, a way to selectively activate the cell’s own renewal machinery without the side effects of systemic approaches,” said Dr. Elias Adriaenssens, Research Institute of Molecular Pathology (IMP), Vienna. “Countdown’s investment gives us the runway to do the work that makes rational drug design possible.” 

The grant is made in honor of Countdown board member Gerry King, whose commitment to advancing mitochondrial research while living with Parkinson’s disease reflects the urgency and importance of this work. 

“We are all overwhelmed by the endless requests for support across countless causes and organizations,” said Gerry King, Countdown Board Member. “I made the decision to place my commitment behind Countdown because of its uncompromising passion to uncover the root causes beneath diseases affecting all walks of life. Mitochondrial dysfunction impacts all of us, and I believe mitochondrial research has the potential to change not only the lives of people living with Parkinson’s disease, but the future of human health itself. My support of Countdown and this mission will continue until meaningful breakthroughs — and ultimately cures — are found.” 

 Founded on the belief that mitochondrial health is not a niche concern but a window into nearly every major disease challenge of our time, Countdown funds research across six interconnected pillars — Early Detection & Precision Diagnostics, Women’s Health & Hormonal Longevity, Primary Mitochondrial & Rare Genetic Disease, Chronic Disease & Aging, Brain Energy & Cognitive Resilience, and Advanced Therapeutics & Frontier Innovation. The organization unites scientists, clinicians, philanthropists, and industry partners to move the field forward faster, accelerating discoveries that shape a future where mitochondrial science is central to how we understand, treat, and prevent disease.

About Countdown 

Countdown is a nonprofit focused on accelerating mitochondrial science and medicine across the full spectrum of human health to improve how people feel, function, and age. By focusing on mitochondria — the shared biological network underlying many of the most pressing diseases of our time — Countdown is driving a more integrated approach to accelerating scientific breakthroughs that transform how we understand, prevent, and treat disease at its source. We fund research, expand awareness, and unite scientists, clinicians, philanthropists, industry leaders, and visionary brands to drive real-world impact. Join the Countdown to change the future of health. 

For more information, visit www.joincountdown.org 

About Elias Adriaenssens
Elias Adriaenssens is a postdoctoral researcher in the laboratory of Tim Clausen at the Research Institute of Molecular Pathology (IMP) at the Vienna BioCenter. He joined the Vienna BioCenter in 2019 as a postdoctoral researcher at the neighbouring Max Perutz Labs.

Adriaenssens completed his PhD in molecular biology at the University of Antwerp in Belgium. He also holds a Master’s degree in pharmacology from the University of Oxford (2014), as well as undergraduate and Master’s degrees in biochemistry from the University of Antwerp.

He has received several awards and honours, including a Medical Research Council (MRC) Studentship Award (2013) / Wolfson College High Profile Achievement Award (2014); a Rotary Hope-in-Head Grant (2019); and a Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship.

About the IMP
The Research Institute of Molecular Pathology (IMP) in Vienna is a basic life science research institute largely sponsored by Boehringer Ingelheim. With over 220 scientists from 40 countries, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. The IMP is part of the Vienna BioCenter, one of Europe’s most dynamic life science hubs with 2,800 staff members from over 80 countries in seven research institutions, two universities, and 42 biotech companies. www.imp.ac.at, www.viennabiocenter.org  

Follow Countdown on Instagram, Facebook, LinkedIn, X and YouTube

Contact:
Mitzi Solomon, Founder and President
[email protected] | +1 (917) 715-2381


GLOBENEWSWIRE (Distribution ID 9721487)

Power of Diversity Grants 2026 – Call for Proposals

Bonn, Germany, May 15, 2026 (GLOBE NEWSWIRE) — Opportunity crops are getting a boost in six countries thanks to the Power of Diversity Funding Facility. On 12 May 2026, the Facility issued a Call for Proposals, officially launching a EUR 2.2 million grant program in Kenya, Nigeria, Zambia, Tanzania, Uganda and Colombia. The Power of Diversity Grants program is calling for proposals to support targeted action in those countries to improve production, processing and consumer awareness of opportunity crops.
The Power of Diversity Grants program will fund targeted projects that strengthen the value chains of selected opportunity crops – nutritious, climate-resilient crops that are well adapted to challenging environments but remain underutilized. Specific target crops for increased investments were identified through national stakeholder consultations in the six countries in 2025.
Each grant will fund a high-impact, scalable project that strengthens specific opportunity crop value chains. The project should address one or several of the intervention areas for each value chain and crop, as national stakeholders identified potential to:

  • Increase productivity through seed system development and good agricultural practices
  • Strengthen post-harvest and processing capacities
  • Improve market access and enhance value chain efficiency 
  • Increase consumer awareness

Enhancing the value chains of opportunity crops holds great potential to provide better nutrition, open economic opportunities and improve lives and livelihoods for communities. The Power of Diversity Grants program marks a step forward for investment into these opportunity crops and for resilience and food security in these countries.

Apply for a Power of Diversity Grant

To apply for a Power of Diversity Grant 2026, please follow this step-by-step guide to see if your organization is eligible and instructions on how to submit a proposal.  

  1. Check the countries, crops and activities – The Funding Facility is working with stakeholder-selected crops in specific countries. Value chain analyses have identified 24 intervention areas, with a specific scope of activity to strengthen the value chain identified by crop and country. See more details on the scope of activities in the table below and at the Power of Diversity Grants online portal.
  2. Check your eligibility – Technical eligibility based on in-country experience and expertise is required, along with financial capacity. Check to ensure your organization has the required experience and capacity to manage the project. 
  3. Propose a project – Eligible organizations are invited to propose a targeted project to enhance the value chain of a specific crop or crops as outlined in the identified intervention for that crop.
  4. Submit your proposal – Visit the Power of Diversity Grants online portal to review and download all application documents. Then, complete and upload the documents and answer all eligibility questions to submit your proposal.

The Crop Trust is looking to find the best fit to deliver positive impact, whether its for pigeon pea seed systems in Nigeria or consumer awareness of chayote in Colombia. All organizations are invited to explore the project interventions, find your fit and submit a proposal.

Countries, Crops and Activities

The Power of Diversity Grants 2026 will be awarded to promote specific opportunity crops selected by stakeholders in countries supported by the Power of Diversity Funding Facility. Project proposals should be relevant to the following countries and crops, with specific intervention scope of activities for each crop available below.

Applicant Eligibility

Grant applicants should be organizations that demonstrate the experience, expertise and eligibility to perform all proposed activities. Technical eligibility must include in-country experience of at least three years. Applicants must be able to prove their annual average revenue turnover from 2023 to 2025 exceeds their proposed project budget, with the budget amounts specified in scope of activities and usually ranging from 100,000 to 200,000 USD. Proposals can be submitted for one or multiple project intervention areas. 

Proposal Parameters

Proposals should present a clear and coherent project logic that demonstrates how the proposed activities will achieve the aims of the intervention outlined. Please note that a proposal may include one or more crops and activities in one or more countries, and each should include:

  • Defined activities and expected results
  • Timeline of project activities, milestones and deliverables
  • A project pathway to scale and sustainability elements
  • Integration of crop diversity conservation and use, including the role of national genebanks 
  • Strong linkages with existing initiatives and stakeholders
  • A cost proposal that is well-justified and aligned with proposed activities

Submit the Proposal

Proposals must be completed using the provided templates and submitted through the Power of Diversity Grants online portal. All templates are available on the Portal. 
To answer any questions about the project or process to apply, a virtual briefing session will be held on 29 May at 3:00 pm CEST. Registration is required, so please register today to attend. Questions for response at the briefing session must be submitted in advance by 25 May by email at [email protected].   
Submissions outside of the portal will not be accepted. Proposals, including all accompanying documentation, should be submitted in English. Questions should be addressed to [email protected].

Proposal Timeline

  • Application deadline – 3 July 2026
  • Notification of successful grantees – 10 August 2026
  • Project kick-off – 1 October 2026
  • Project completion deadline – Before 31 March 2029 

Selection Procedure 

All applications will be reviewed by an expert panel established by the Crop Trust. Proposals will compete with other interventions in the value chain, as well as with similar types of interventions across value chains. The selection process aims to ensure a portfolio of interventions that covers all value chains and pilots a variety of approaches from seed systems to consumer awareness. 
The selection panel may contact applicants to request any necessary clarifications regarding the received proposals. Approval of an application does not guarantee project funding. Crop Trust reserves the right to sustain or abandon the call for proposals at any time before the signing of the contract.

Attachments


GLOBENEWSWIRE (Distribution ID 9721157)

Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026

INFORMATIONS RÉGLEMENTÉES

Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026

Le lancement réussi de Genio aux États-Unis génère une croissance trimestrielle séquentielle de 25 % du chiffre d'affaires américain
Clarification continue du remboursement de l'HGNS et de Genio aux États-Unis

Mont-Saint-Guibert, Belgique – 12 mai 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale dédiée au développement et à la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (AOS), a publié aujourd'hui ses résultats financiers et opérationnels du premier trimestre 2026.

Temps Forts Financiers et Opérationnels

  • Financiers
    • Chiffre d'affaires net aux États-Unis du premier trimestre 2026 de 4,3 millions d'euros (chiffre d'affaires brut de 4,5 millions d'euros), soit une croissance séquentielle de 25 % par rapport au chiffre d'affaires net du quatrième trimestre 2025
    • Chiffre d'affaires net mondial du premier trimestre 2026 de 6,4 millions d'euros (chiffre d'affaires brut de 6,7 millions d'euros), soit une croissance séquentielle de 13 % par rapport au chiffre d'affaires net du quatrième trimestre 2025
  • Principaux indicateurs commerciaux aux États-Unis
    • 62 nouveaux chirurgiens formés au T1, portant le total à 207 chirurgiens formés
    • 34 nouveaux comptes activés au T1, portant le total à 91 comptes actifs à fort volume
    • 241 patients dont la demande d'autorisation préalable a été soumise et qui étaient toujours en attente à la fin du premier trimestre
  • Environnement de remboursement aux États-Unis – clarification approfondie
    • Medicare a publié de nouveaux C-Codes couvrant Genio et a clarifié les paiements aux établissements et aux médecins
    • Les organismes payeurs privés ont poursuivi le remboursement selon les codes CPT existants
    • Taux d'approbation de 100 % obtenu sur les autorisations préalables clôturées auprès des organismes payeurs privés et du programme WISeR
  • Au 31 mars 2026, la trésorerie, les équivalents de trésorerie et les actifs financiers s'élevaient à 25,9 millions d'euros. Au deuxième trimestre 2026, la Société prévoit de tirer 13,8 millions d'euros de la deuxième tranche du prêt de la Banque européenne d'investissement.

“Nos résultats de chiffre d'affaires du premier trimestre reflètent une exécution solide de notre lancement aux États-Unis. La croissance trimestrielle séquentielle de 25 % du chiffre d'affaires a été portée par une activité soutenue dans les sites existants et une forte progression des ouvertures de nouveaux sites. Nous continuons d'observer un environnement de remboursement stable et avons enregistré un taux d'approbation de 100 % sur les soumissions d'autorisation préalable clôturées aux États-Unis à la fin du T1 2026. Le remboursement n'a pas freiné nos résultats du premier trimestre,” a commenté Olivier Taelman, Chief Executive Officer de Nyxoah. “Alors que nous entamons notre troisième trimestre complet de commercialisation aux États-Unis, nous restons concentrés sur l'élargissement de l'activation des comptes, le traitement d'un plus grand nombre de patients dans les comptes actifs et le maintien d'une discipline opérationnelle afin d'assurer une croissance durable du chiffre d'affaires aux États-Unis.”

Résultats pour le Trimestre Clos le 31 Mars 2026

Chiffre d'affaires

Le chiffre d'affaires brut du premier trimestre 2026 s'est élevé à 6,7 millions d'euros, avant 0,3 million d'euros de produits différés principalement liés aux patchs jetables livrés au fil du temps. Le chiffre d'affaires net s'est établi à 6,4 millions d'euros, contre 1,1 million d'euros au premier trimestre 2025. La progression du chiffre d'affaires net est principalement portée par la poursuite de l'expansion des activités de commercialisation aux États-Unis à la suite de l'autorisation de la FDA obtenue en août 2025, ainsi que par la croissance sur les marchés internationaux.

Coût des biens vendus
Le coût des biens vendus s'est élevé à 2,7 millions d'euros au premier trimestre 2026, générant un bénéfice brut de 3,6 millions d'euros et une marge brute de 57 %, contre un coût des biens vendus de 0,4 million d'euros et une marge brute de 62 % au premier trimestre 2025. La hausse du coût des biens vendus reflète les volumes supérieurs liés à la commercialisation aux États-Unis. La baisse de la marge brute s'explique par des problèmes de rendement de production qui ont été résolus.

Recherche et Développement
Au premier trimestre 2026, les charges de recherche et développement se sont élevées à 8,8 millions d'euros, contre 9,0 millions d'euros au premier trimestre 2025. La baisse des charges de recherche et développement reflète la réduction des investissements dans les coûts d'études cliniques telles que DREAM et ACCCESS.

Frais de vente, généraux et administratifs
Au premier trimestre 2026, les frais de vente, généraux et administratifs se sont élevés à 15,4 millions d'euros, contre 12,4 millions d'euros au premier trimestre 2025. La hausse des frais de vente, généraux et administratifs s'explique principalement par la poursuite du développement de l'organisation commerciale de la Société aux États-Unis, incluant les fonctions de vente, marketing et accès au marché.

Perte d'exploitation
La perte d'exploitation totale du premier trimestre 2026 s'est élevée à 20,5 millions d'euros, contre 20,6 millions d'euros au premier trimestre 2025. L'évolution de la perte d'exploitation reflète la hausse du chiffre d'affaires net, compensée par l'augmentation des investissements commerciaux soutenant les activités de lancement aux États-Unis, ainsi que par la poursuite des investissements en recherche et développement.

Trésorerie
La trésorerie, les équivalents de trésorerie et les actifs financiers s'élevaient à environ 25,9 millions d'euros au 31 mars 2026.
Au deuxième trimestre 2026, la Société prévoit de tirer 13,8 millions d'euros de la deuxième tranche du prêt de la Banque européenne d'investissement.

Prévisions Financières pour le Deuxième Trimestre 2026 et l'Exercice Complet 2026

  • La Société prévoit une croissance séquentielle du chiffre d'affaires net aux États-Unis du deuxième trimestre 2026 d'environ 25-30 % par rapport au premier trimestre 2026.
  • La Société prévoit un chiffre d'affaires net mondial pour l'exercice complet 2026 compris entre 36 et 40 millions d'euros.
  • La Société prévoit une marge brute pour l'exercice complet 2026 comprise entre 60 % et 62 %.
  • La Société prévoit des charges d'exploitation totales pour l'exercice complet 2026 comprises entre 97 et 99 millions d'euros. La Société prévoit des charges d'exploitation décaissables non-GAAP pour l'exercice complet 2026 comprises entre 88 et 90 millions d'euros. Les charges d'exploitation décaissables non-GAAP correspondent aux charges d'exploitation totales prévues, diminuées des charges non décaissables telles que les amortissements, les dépréciations et les paiements fondés sur des actions.

Conférence téléphonique et webcast
La direction de la Société tiendra une conférence téléphonique pour commenter les résultats financiers le mardi 12 mai 2026, à partir de 22h30 CET / 16h30 ET.

Une retransmission webcast de l'appel sera accessible via la page Investor Relations du site internet de Nyxoah ou via le lien suivant : Nyxoah's Q1 2026 Earnings Call Webcast. Pour les personnes ne souhaitant pas poser de question à la direction, la Société recommande de suivre l'appel via le webcast.

Si vous prévoyez de poser une question, veuillez utiliser le lien suivant : Nyxoah's Q1 2026 Earnings Call Q&A Link. Après inscription, un courriel vous sera envoyé contenant les coordonnées de connexion ainsi qu'un code d'accès unique à la conférence requis pour rejoindre l'appel en direct. Afin d'assurer une connexion en amont du début de l'appel, la Société suggère de s'inscrire au moins 10 minutes avant son démarrage.

Le webcast archivé sera disponible en différé peu après la fin de l'appel.

Mesures financières non-GAAP
Le présent communiqué de presse inclut des mesures financières non-GAAP (Generally Accepted Accounting Principles), notamment les charges d'exploitation décaissables non-GAAP. Les charges d'exploitation décaissables non-GAAP sont calculées en excluant des charges d'exploitation GAAP certains éléments, dont les amortissements, les dépréciations, les charges de recherche et développement capitalisées, les pertes de valeur sur immobilisations incorporelles, et les paiements fondés sur des actions. Ces mesures financières non-GAAP sont présentées parce que la Société estime qu'elles constituent des indicateurs utiles de sa performance opérationnelle. La direction utilise ces mesures financières non-GAAP pour évaluer la performance opérationnelle de la Société et à des fins de planification, notamment dans le cadre de la préparation du budget opérationnel annuel et des projections financières de la Société. La Société considère que ces mesures sont utiles aux investisseurs en tant qu'information complémentaire, dans la mesure où elles sont fréquemment utilisées par les analystes, les investisseurs et d'autres parties intéressées pour évaluer les sociétés du secteur. Ces mesures financières non-GAAP ne doivent pas être considérées comme des alternatives ni comme supérieures à toute autre mesure de performance établie conformément aux normes GAAP. Elles ne doivent pas être interprétées comme signifiant que les résultats futurs de la Société ne seront pas affectés par des éléments inhabituels ou non récurrents. Les définitions de la Société pour les charges d'exploitation décaissables non-GAAP ne sont pas nécessairement comparables aux libellés similaires utilisés par d'autres sociétés en raison de méthodes de calcul différentes.

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d'Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d'Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l'étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l'une sur Euronext Bruxelles en septembre 2020 et l'autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l'extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre-indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous-groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d'informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

DÉCLARATIONS PROSPECTIVES

Certaines déclarations, convictions et opinions contenues dans le présent communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah concernant l'utilisation potentielle du système Genio ; la stratégie de commercialisation de la Société et son entrée sur le marché américain ; les résultats d'exploitation, la situation financière, la liquidité, la performance, les perspectives, la croissance, les revenus futurs, les charges d'exploitation futures, les marges brutes futures et les stratégies de la Société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs susceptibles d'entraîner une différence significative entre les résultats ou événements réels et ceux exprimés ou sous-entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir un impact négatif sur l'issue et les conséquences financières des projets et événements décrits dans le présent document. Ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes exposés dans la section « Facteurs de risque » du rapport annuel de la Société sur le formulaire 20-F pour l'exercice clos le 31 décembre 2025, déposé auprès de la Securities and Exchange Commission (« SEC ») le 26 mars 2026, ainsi que dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent entraîner des événements, des performances ou des résultats réels sensiblement différents de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant des tendances ou des activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une assurance que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou les développements réels correspondent aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements à venir. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. En conséquence, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, conditions, hypothèses ou circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni les dirigeants ou employés de ces entités ne garantissent que les hypothèses sous-jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

COMPTES CONSOLIDÉS DE PERTE ET DE PERTE GLOBALE (non audités) (en milliers)

Pour les trois mois clôturés au 31 mars,

      2026 2025
Chiffre d'affaires     € 6 372 € 1 064
Coût des biens vendus     (2 734) (406)
Bénéfice brut     € 3 638 € 658
Charges de recherche et développement     (8 804) (8 989)
Frais de vente, généraux et administratifs     (15 374) (12 392)
Autres revenus     40 84
Perte d'exploitation de la période     € (20 500) € (20 639)
Produits financiers     6 982 2 622
Charges financières     (2 036) (4 242)
Perte de la période avant impôts     € (15 554) € (22 259)
Impôts sur le résultat     (390) (125)
Perte de la période     € (15 944) € (22 384)
         
Perte attribuable aux détenteurs de capitaux propres     € (15 944) € (22 384)
Perte globale        
Éléments susceptibles d'être ultérieurement reclassés en résultat (net d'impôt)        
Écarts de conversion de devises     (309) (2)
Perte globale totale de l'exercice, nette d'impôt     € (16 253) € (22 386)
Perte attribuable aux détenteurs de capitaux propres     € (16 253) € (22 386)
         
Perte de base par action (en EUR)     € (0.369) € (0.598)
Perte diluée par action (en EUR)     € (0.369) € (0.598)

ÉTAT CONSOLIDÉ DE LA SITUATION FINANCIÈRE (non audité) (en milliers)
       
      Au
      31 mars 2026   31 décembre 2025
ACTIFS          
Actifs non courants          
Immobilisations corporelles     3 930   4 052
Immobilisations incorporelles     49 237   50 108
Droits d'utilisation     2 061   1 293
Actif d'impôt différé     11   87
Autres créances à long terme     1 793   1 718
      € 57 032   € 57 258
Actifs courants          
Stocks     4 348   4 660
Créances clients     6 325   5 254
Actifs sur contrats     243   261
Autres créances     2 645   2 209
Autres actifs courants     1 071   828
Actifs financiers     13 000   18 000
Trésorerie et équivalents de trésorerie     12 934   30 001
      € 40 566   € 61 213
Total des actifs     € 97 598   € 118 471
           
CAPITAUX PROPRES ET PASSIFS          
Capital social et réserves          
Capital social     6 511   6 505
Prime d'émission     337 242   335 134
Réserve de paiements fondés sur des actions     13 031   12 395
Autres éléments du résultat global     815   1 124
Pertes accumulées     (321 728)   (306 029)
Total des capitaux propres attribuables aux actionnaires     € 35 871   € 49 129
           
PASSIFS          
Passifs non courants          
Dette financière     17 435   17 670
Obligations locatives     1 453   637
Provisions     1 039   1 396
Passif d'impôt différé     34   −
Passif sur contrats     709   681
      € 20 670   € 20 384
Passifs courants          
Dette financière     16 471   22 990
Obligations locatives     721   779
Dettes fournisseurs     12 638   13 727
Passif d'impôt courant     4 355   3 939
Passif sur contrats     1 120   894
Autres passifs     5 752   6 629
      € 41 057   € 48 958
Total des passifs     € 61 727   € 69 342
Total des capitaux propres et passifs     € 97 598   € 118 471

Mesures Financières Non-GAAP

Les tableaux suivants présentent un rapprochement des charges d'exploitation GAAP avec les charges d'exploitation décaissables non-GAAP pour les trois mois clôturés au 31 mars 2026 et 2025, respectivement.

  Pour les trois mois clôturés au 31 mars,
Non audité – En milliers 2026 2025
Charges d'exploitation R&D GAAP € 8 804 €8 989
Amortissements et dépréciations (1 276) (411)
Dépréciation d'immobilisations incorporelles – –
Paiements fondés sur des actions (78) (310)
R&D capitalisée 159 864
Charges d'exploitation R&D décaissables non-GAAP € 7 609 €9 132
     
Charges d'exploitation SG&A GAAP €15 374 €12 392
Amortissements (440) (363)
Paiements fondés sur des actions (803) (1 665)
Charges d'exploitation SG&A décaissables non-GAAP €14 131 €10 364

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001181610)

Nyxoah Reports First Quarter 2026 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports First Quarter 2026 Financial and Operating Results

Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth
Continued clarity around HGNS and Genio reimbursement in the U.S.

Mont-Saint-Guibert, Belgium – May 12, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2026.

Q1 2026 Financial and Operating Highlights

  • Financials
    • U.S. net revenue first quarter 2026 was €4.3 million (gross revenue was €4.5 million), 25% sequential growth over net revenue fourth quarter 2025
    • Global net revenue first quarter 2026 was €6.4 million (gross revenue was €6.7 million), 13% sequential growth over net revenue fourth quarter 2025
  • Leading U.S. commercial indicators
    • 62 new surgeons trained in Q1, bringing the total to 207 surgeons trained
    • 34 new accounts activated in Q1, bringing the total to 91 active high-volume accounts
    • 241 patients submitted under prior authorization and still pending at the end of Q1
  • U.S. reimbursement landscape – further clarified
    • Medicare issued new C-Codes covering Genio and clarified facility and physician payments
    • Commercial payers continued reimbursement under existing CPT codes
    • 100% prior-authorization approval obtained on reviewed submissions with commercial payers and WISeR program
  • As of March 31, 2026, cash, cash equivalents and financial assets amounted to €25.9 million. In the second quarter of 2026, the Company expects to draw €13.8 million from the second tranche of the European Investment Bank loan.

“Our first quarter revenue results reflect strong execution of our U.S. launch. The 25% sequential quarterly revenue growth was driven by continued strong activity in existing sites, and high growth in new site openings. We continue to see a consistent reimbursement landscape and had a 100% approval rate on closed U.S. prior authorization submissions as of the end of Q1 2026. Reimbursement did not hinder our first quarter results,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “Entering our third full quarter of U.S. commercialization, we remain focused on further expanding account activation, treating more patients in active accounts and maintaining operating discipline to deliver sustainable revenue growth in the U.S.”

Results for the Three Months Ended March 31, 2026

Revenue

Gross revenue for the first quarter of 2026 was €6.7 million before €0.3 million of deferred revenue mainly related to disposable patches which are delivered over time. Net revenue was €6.4 million, compared to €1.1 million in the first quarter of 2025. The increase in net revenue was primarily driven by the continued expansion of U.S. commercialization activities following FDA approval in August 2025, as well as growth in international markets.

Cost of Goods Sold
Cost of goods sold was €2.7 million for the first quarter of 2026, resulting in a gross profit of €3.6 million and a gross margin of 57%, compared to cost of goods sold of €0.4 million and a gross margin of 62% in the first quarter of 2025. The increase in cost of goods sold was driven by higher volumes associated with the U.S. commercialization. The decrease in gross margin reflects production yield issues which have been addressed.

Research and Development
For the first quarter of 2026, research and development expenses were €8.8 million, versus €9.0 million for the first quarter of 2025. The decrease in research and development expenses reflects reduced investments in clinical study costs such as DREAM and ACCCESS.

Selling, General and Administrative
For the first quarter of 2026, selling, general and administrative expenses were €15.4 million, versus €12.4 million for the first quarter of 2025. The increase in selling, general and administrative expenses was primarily driven by the continued build-out of the Company’s U.S. commercial organization, including sales, marketing, and market access functions.

Operating Loss
Total operating loss for the first quarter of 2026 was €20.5 million, versus €20.6 million in the first quarter of 2025. The change in operating loss reflects increased net revenue offset by increased commercial investments to support U.S. launch activities, as well as continued investment in research and development.

Cash Position
Cash, cash equivalents and financial assets amounted to approximately €25.9 million at March 31, 2026.
In the second quarter of 2026, the Company expects to draw €13.8 million from the second tranche of the European Investment Bank loan.

Financial Guidance for the Second Quarter of 2026 and Full Year 2026

  • The Company expects U.S. net revenue for the second quarter of 2026 to grow sequentially by approximately 25-30% over the first quarter of 2026.
  • The Company expects worldwide net revenue for the full year 2026 to be in the range of €36 million to €40 million.
  • The Company expects the gross margin for the full year 2026 to be in the range of 60% to 62%.
  • The Company expects total operating expenses for the full year 2026 to be in the range of €97 million to €99 million. The Company expects non-GAAP cash operating expenses for the full year 2026 to be in the range of €88 million to €90 million. Non-GAAP cash operating expenses reflect expected total operating expenses less non-cash expenses such as depreciation, amortization, and share-based compensation.

Conference call and webcast presentation
Company management will host a conference call to discuss financial results on Tuesday, May 12, 2026, beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 2026 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah's Q1 2026 Earnings Call Q&A Link. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

Non-GAAP financial measures
This press release includes non-GAAP (Generally Accepted Accounting Principles) financial measures, including non-GAAP cash operating expenses. Non-GAAP cash operating expenses are calculated by excluding from GAAP certain operating expenses items, including depreciation, amortization, capitalized research and development expenses, impairment losses on intangible assets, and share-based compensation. These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these non-GAAP financial measures as measures of the Company's operating performance and for planning purposes, including the preparation of the Company's annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. These non-GAAP financial measures should not be considered alternatives to, or superior to, any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. The Company's definitions of non-GAAP cash operating expenses are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65. 

For more information, please visit http://www.nyxoah.com/. 

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. 

Forward-looking statements  

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited) (in thousands)

For the Three Months Ended March 31,

      2026 2025
Revenue     € 6 372 € 1 064
Cost of goods sold     (2 734) (406)
Gross profit     € 3 638 € 658
Research and Development Expense     (8 804) (8 989)
Selling, General and Administrative Expense     (15 374) (12 392)
Other income     40 84
Operating loss for the period     € (20 500) € (20 639)
Financial income     6 982 2 622
Financial expense     (2 036) (4 242)
Loss for the period before taxes     € (15 554) € (22 259)
Income taxes     (390) (125)
Loss for the period     € (15 944) € (22 384)
         
Loss attributable to equity holders     € (15 944) € (22 384)
Other comprehensive loss        
Items that may be subsequently reclassified to profit or loss (net of tax)        
Currency translation differences     (309) (2)
Total comprehensive loss for the year, net of tax     € (16 253) € (22 386)
Loss attributable to equity holders     € (16 253) € (22 386)
         
Basic Loss Per Share (in EUR)     € (0.369) € (0.598)
Diluted Loss Per Share (in EUR)     € (0.369) € (0.598)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited) (in thousands)
       
      As at
      March 31 2026   December 31 2025
ASSETS          
Non-current assets          
Property, plant and equipment     3 930   4 052
Intangible assets     49 237   50 108
Right of use assets     2 061   1 293
Deferred tax asset     11   87
Other long-term receivables     1 793   1 718
      € 57 032   € 57 258
Current assets          
Inventory     4 348   4 660
Trade receivables     6 325   5 254
Contract assets     243   261
Other receivables     2 645   2 209
Other current assets     1 071   828
Financial assets     13 000   18 000
Cash and cash equivalents     12 934   30 001
      € 40 566   € 61 213
Total assets     € 97 598   € 118 471
           
EQUITY AND LIABILITIES          
Share capital and reserves          
Share capital     6 511   6 505
Share premium     337 242   335 134
Share based payment reserve     13 031   12 395
Other comprehensive income     815   1 124
Retained loss     (321 728)   (306 029)
Total equity attributable to shareholders     € 35 871   € 49 129
           
LIABILITIES          
Non-current liabilities          
Financial debt     17 435   17 670
Lease liability     1 453   637
Provisions     1 039   1 396
Deferred tax liability     34   −
Contract liability     709   681
      € 20 670   € 20 384
Current liabilities          
Financial debt     16 471   22 990
Lease liability     721   779
Trade payables     12 638   13 727
Current tax liability     4 355   3 939
Contract liability     1 120   894
Other liabilities     5 752   6 629
      € 41 057   € 48 958
Total liabilities     € 61 727   € 69 342
Total equity and liabilities     € 97 598   € 118 471

Non-GAAP Financial Measures

The following tables contain a reconciliation of GAAP operating expenses to non-GAAP cash operating expenses for the three months ended March 31, 2026 and 2025, respectively.

  For the Three Months Ended March 31,
Unaudited – In thousands 2026 2025
GAAP R&D Operating Expenses € 8,804 €8,989
Depreciation and amortization (1,276) (411)
Impairment of intangibles – –
Share-based compensation (78) (310)
Capitalized R&D 159 864
Non-GAAP Cash R&D Operating Expenses € 7,609 €9,132
     
GAAP SG&A Operating Expenses €15,374 €12,392
Depreciation (440) (363)
Share-based compensation (803) (1,665)
Non-GAAP Cash SG&A Operating Expenses €14,131 €10,364

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001181610)

Riqueza global ultrapassa fronteiras, 1 em cada 5 ultra ricos agora nasceu no exterior

  • População de Ultra Alto Patrimônio Líquido (UHNW) atingirá 734.100 até 2030, um aumento de 33%
  • O patrimônio líquido combinado dos mais ricos do mundo aumentará para US$ 84 trilhões até 2030
  • Quase 79% são self-made, com apenas 5% herdando sua riqueza

MONTREAL, May 12, 2026 (GLOBE NEWSWIRE) — O último relatório da Altrata, Global Citizens: Entrepreneurship, Mobility and the Ultra Wealthy (Cidadãos do Mundo, Empresariado, Mobilidade e Ultra Ricos), patrocinado pela principal consultoria de migração de investimentos Arton Capital, revelou que 1 em cada 5 indivíduos UHNW do mundo (UHNWI*) nasceram no exterior**, revelando o caráter cada vez mais internacional dos ultra ricos de hoje. O relatório histórico também revelou que a população de UHNW deve aumentar em um terço (33%) para chegar a 734.100 até 2030.

População de Patrimônio Líquido Ultra Alto Deve se Expandir Rapidamente

O relatório prevê um rápido aumento no patrimônio líquido de indivíduos UHNW globais. O patrimônio líquido combinado deve aumentar de US$ 63 trilhões em 2025 para US$ 84 trilhões até o final da década. Até 2030, estima-se que 7,7 milhões de pessoas sejam titulares de mais de US$ 5 milhões em ativos.

Criação de Riqueza Dominada por Pessoas Self-Made com Mentalidade Global

De modo significativo, a pesquisa revela que os indivíduos UHNW nascidos no exterior são, na grande maioria, “criadores de riqueza”, e não herdeiros. Cerca de 79% são self-made, em comparação com 16% que atribuem sua riqueza a uma combinação de empreendedorismo e herança, e apenas 5% cuja riqueza é totalmente herdada.

Os resultados apontam para uma mudança estrutural na forma como a riqueza global é criada e administrada. A riqueza pessoal está se tornando menos ligada a uma única nação, com os mais ricos do mundo tendo a vida, ativos e negócios em locais. Veja como os UHNW de hoje operam em todo o mundo: 17% são proprietários, totais ou parciais, de empresas com sede fora do país de residência, enquanto 34% cursaram ensino superior fora do país de nascimento — ressaltando que a mobilidade transfronteiriça não é acidental, e sim está incorporada na forma como a riqueza moderna é acumulada.

Em conjunto, os dados revelam uma clara relação entre a mobilidade e o empreendedorismo. Pessoas com mobilidade internacional são mais propensas a criar empresas, buscar oportunidades além das fronteiras e gerar sua própria riqueza – refletindo um grupo definido pela ambição, apetite ao risco e acesso aos mercados globais. A mobilidade, neste contexto, é um facilitador fundamental para a criação de riqueza moderna.

Vidas Transfronteiriças Tornam-se a Norma para os Ultra-Ricos

Embora a riqueza seja cada vez mais transfronteiriça, as principais cidades globais continuam sendo os centros primários para pessoas UHNW.

Londres continua sendo um centro proeminente para pessoas UHNW, principalmente para quem pertence ao setor bancário e financeiro, apesar dos crescentes contratempos, incluindo regimes fiscais mais rígidos e restrições comerciais.

Por outro lado, os EUA continuam sendo o principal centro de riqueza do mundo, com cerca de 40% da população global de UHNW (205.000), destacando sua constante atração, mesmo em meio a mudanças na dinâmica política. No entanto, a evolução das condições políticas pode começar a influenciar os fluxos futuros, com pesquisas anteriores da Arton Capital indicando que um terço dos milionários americanos*** considerou deixar os EUA devido ao impacto da presidência de Trump.

No Golfo, Dubai consolida sua reputação de “centro de riqueza jovem” para as elites globais, com quase um quinto (19%) das pessoas UHNW com menos de 50 anos de idade na cidade nascidas no exterior. Seu status, apesar das tensões geopolíticas em curso no Oriente Médio, indica uma tendência mais ampla: As pessoas UHNW não estão se afastando do movimento global, e sim se tornando mais estratégicas em como e onde fazem uso dele.

Armand Arton, CEO da Arton Capital, comentou: “A mobilidade global não é mais um subproduto da criação da riqueza – e sim um ativo estratégico que a sustenta. As pessoas de sucesso de hoje não estão apenas criando negócios – elas estão criando acesso a: mercados, talentos, educação e segurança de longo prazo em vários locais.”

“O que estamos vendo é uma dissociação entre a riqueza e a localização geográfica. As pessoas de maior sucesso estão estruturando a vida e ativos em várias locais, reduzindo a dependência de um único país. A próxima geração de pessoas UHNW está pensando além das soluções em um único país, priorizando a flexibilidade, a resiliência e a opcionalidade de como e onde viver, investir e aumentar a riqueza. Em um mundo cada vez mais complexo, a capacidade de atravessar fronteiras sem problemas está se tornando uma das ferramentas mais potentes para a criação e preservação da riqueza.”

Moira Boyle, Diretora Sênior, Dirigente Global de Luxo da Altrata, disse: “O que se destaca nesta pesquisa é o aumento contínuo da criação de riqueza empresarial em nível global. Quase 80% das pessoas ultra-ricas nascidas no exterior são self-made, indicando que a riqueza de hoje está cada vez mais sendo impulsionada pela inovação, ambição e criação de negócios.

“Por outro lado, a população de UHNW está se expandindo rapidamente, com a riqueza e a influência total devendo crescer significativamente até o final da década. Para as organizações, entender quem são essas pessoas e como sua riqueza é criada é essencial para identificar oportunidades, criar relacionamentos e se manter competitivo em um mercado em rápida evolução.”

Notas as Editor

*Patrimônio Líquido Ultra Alto definido como pessoas com mais de US$ 30 milhões em patrimônio líquido.

**Os ricos nascidos no exterior são definidos como pessoas com mais de US$ 30 milhões em patrimônio líquido que nasceram fora do país de residência e onde seu principal negócio está localizado.

***Entre 9 de janeiro de 2026 e 14 de janeiro de 2026, a Arton Capital entrevistou 1.000 residentes dos EUA com idade entre 18 e 70 anos com patrimônio líquido de pelo menos US$ 1 milhão. 33% dos entrevistados disseram que estavam mais propensos a deixar os EUA agora do que antes das eleições presidenciais de 2024.

** ** Cidadãos globais é um termo usado de forma intercambiável no relatório com ricos nascidos no exterior

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/85811040-92fb-42c9-bb5d-92088ad73e53


GLOBENEWSWIRE (Distribution ID 9718538)

الثروة العالمية تتخطى الحدود الجغرافية: واحد من كل خمسة من أصحاب الثروات الفائقة مولود خارج البلد الذي يقيم فيه

  • من المتوقع أن يشهد عدد الأفراد ذوي الثروات الفائقة (UHNW) نمواً سريعاً بنسبة تقارب 33% ليصل إلى نحو 734،100 فرد بحلول عام 2030
  • سيبلغ صافي الثروة المجمّعة لأغنى أغنياء العالم 84 تريليون دولار بحلول عام 2030
  • تشير الإحصائيات أن نحو 79% من الأثرياء هم من العصاميين الذين صنعوا ثرواتهم بأنفسهم، مقابل 5% فقط ورثوا ثرواتهم بالكامل

مونتريال, May 12, 2026 (GLOBE NEWSWIRE) —

 كشف تقرير حديث أصدرته مؤسسة Altrata المتخصّصة في أبحاث الثروات بالتعاون مع Arton Capital، الشركة العالمية الرائدة في مجال استشارات الهجرة الاستثمارية، عن تحولات جوهرية في ملامح النخبة العالمية من أصحاب الثروات الفائقة. وأشار التقرير، الذي يحمل عنوان “المواطنون العالميون: ريادة الأعمال، والتنقل، والأثرياء” (Global Citizens: Entrepreneurship, Mobility and the Ultra Wealthy)، إلى أن واحداً من كل خمسة من الأفراد ذوي الثروات الفائقة (UHNWI*) هو من المولودين خارج بلدهم الأم**، ما يؤكد الطابع الدولي المتنامي للنخبة الثرية. كما توقّع التقرير أن يشهد عدد الأفراد ذوي الثروات الفائقة نمواً متسارعاً بمعدل يزيد عن الثلث (33%) خلال السنوات المقبلة ليصل إلى 734،100 فرد بحلول عام 2030.

توسع لافت ومتسارع قاعدة أصحاب الثروات الفائقة عالمياً

سلّط التقرير الضوء على النمو القياسي المتوقّع في ثروات هذه الشريحة العالمية من أصحاب الثروات الفائقة (UHNW)، مشيراً إلى أن صافي الثروة المجمّعة لأغنى أغنياء العالم مرشّح للارتفاع من 63 تريليون دولار في عام 2025 إلى 84 تريليون دولار بحلول نهاية هذا العقد. وفي السياق ذاته، توقع التقرير أن يصل عدد الأفراد الذين تتجاوز أصولهم 5 ملايين دولار نحو 7.7 مليون شخص عالميًا بحلول 2030، ما يعكس تسارع وتيرة توسّع الثروة.    

صُنّاع الثروة الجدد: أفراد عصاميون ذوي رؤية عالمية يقودون مشهد الثراء

توضح الأبحاث أن الغالبية الساحقة من أصحاب الثروات الفائقة (UHNW) المولودين خارج بلدانهم الأصلية ينتمون إلى فئة روّاد الأعمال “العصاميين”، إذ ساهم نحو 79% منهم بجهدهم الشخصي لتكوين ثرواتهم بأنفسهم من الصفر، مقارنة بـ 16% من روّاد الأعمال ممن ينسبون ثروتهم إلى مزيج من ريادة الأعمال والإرث، و5% فقط ممن ورثوا ثرواتهم بالكامل.

هذا وتكشف نتائج التقرير عن تحولٍ بنيوي في آليات توليد وإدارة الثروة العالمية، إذ لم تعد الثروة الشخصية مرتبطة حصرياً بدولة واحدة أو سوق محلية واضحة، مع قيام الأثرياء بتوزيع أنماط حياتهم وأصولهم واستثماراتهم وأعمالهم عبر عدة دول وولايات قضائية حول العالم. يتجلّى هذا التحوّل بشكل واضح في سلوك أصحاب الثروات الفائقة عالمياً، حيث يمتلك 17% منهم شركات أو حصصاً في شركات يقع مقرها في دول خارج بلد إقامتهم، في حين تلقى 34% تعليمهم العالي خارج بلدهم الأم. تؤكد هذه المعطيات أن التنقل الدولي لم يعد مجرد خيار ثانوي أو نمط حياة متصل بالرفاهية، بل أصبح مكوّناً أساسياً في آليات صناعة الثروة الحديثة.

وبشكل عام، تُظهر البيانات ترابطاً وثيقاً وعلاقة تكاملية بين التنقل العالمي وريادة الأعمال، حيث يميل الأفراد الأكثر تنقّلاً عبر الحدود إلى تأسيس الأعمال واستغلال الفرص الاستثمارية العالمية وتكوين ثرواتهم بأنفسهم. تعكس هذه السمات جيلاً جديداً من رواد الأعمال تتسم بالطموح والاستعداد لخوض المخاطر، إلى جانب قدرة عالية على الوصول إلى الأسواق العالمية والاستفادة منها. وفي هذا السياق، يبرز التنقل كعامل رئيسي في تمكين صناعة الثروة الحديثة.

الحياة العابرة للحدود تترسخ كنمط طبيعي لأصحاب الثروات الفائقة

على الرغم من تزايد عالمية الثروة وتسارع انتقالها عبر الحدود، لا تزال بعض المدن تشكّل مراكز جذب رئيسية تستقطب أصحاب الثروات الفائقة من مختلف أنحاء العالم.

وتحافظ لندن على مكانتها كإحدى أبرز هذه الوجهات، لا سيما بالنسبة إلى رواد قطاعي المصارف والخدمات المالية، رغم الضغوط المتنامية الناتجة عن تشديد القواعد الضريبية والقيود التجارية.

في الوقت نفسه، تواصل الولايات المتحدة الأمريكية ترسيخ مكانتها في الصدارة عالمياً، إذ تحتضن نحو 40% من إجمالي أصحاب الثروات الفائقة حول العالم، بما يعادل 205 آلاف شخص، في دلالة على استمرار جاذبيتها الاقتصادية رغم المشهد السياسي المتقلب. ومع ذلك، تشير المؤشرات إلى أن التحولات السياسية والسياسات الداخلية قد تعيد رسم اتجاهات تدفقات الثروة العالمية خلال السنوات المقبلة. فقد أظهرت دراسات سابقة نفّتها Arton Capital إلى أن واحداً من كل ثلاثة مليونيرات أميركيين*** فكر في مغادرة البلاد نتيجة تداعيات رئاسة Donald Trump. 

وفي منطقة الخليج، تواصل دبي ترسيخ مكانتها كمركز عالمي “للثروة الشابة”، ووجهة مفضّلة تستقطب النخب العالمية، حيث تشير البيانات إلى أن خُمس الأفراد (19%) من أصحاب الثروات الفائقة (UHNW) المولودين خارج الدولة والمقيمين في المدينة، تقلّ أعمارهم عن 50 عاماً. ورغم التوترات الجيوسياسية المستمرة في منطقة الشرق الأوسط، تعكس هذه المكانة توجّهاً عالمياً جديداً في سلوك أصحاب الثروات الفائقة، الذين باتوا أكثر انتقائية واستراتيجية في اختيار أماكن إقامتهم وتحركاتهم الدولية وتوزيع استثماراتهم العابرة للحدود.

وفي هذا السياق، قال Armand Arton، الرئيس التنفيذي لشركة Arton Capital: “لم تعد حركة التنقل العالمي مجرد نتيجة ثانوية بالنسبة للأثرياء، بل أصبحت جزءاً استراتيجياً من معادلة بناء الثروة. فالأفراد الناجحون لا يكتفون حالياً ببناء الشركات، إنما يسعون أيضاً إلى بناء منظومات وصول متكاملة تتيح لهم الاستفادة من الأسواق والمواهب والتعليم والأمن طويل الأجل عبر نطاقات قضائية متعددة.”

وأضاف: “يشهد العالم حالياً تحولاً واضحاً يتمثل في انفصال الثروة عن الحدود الجغرافية، حيث يقوم الأثرياء الناجحون بتوزيع أصولهم وحياتهم عبر عدة دول، بما يمنحهم مرونة أكبر ويحد من مخاطر الاعتماد على بلد واحد. كذلك، لم يعد الجيل الجديد من أصحاب الثروات الفائقة (UHNW) يكتفي بالحلول المحصورة في دولة واحدة، إنما يفضلون نماذج أكثر مرونة واستدامة، مع اهتمام متزايد بتعدد خيارات الإقامة والاستثمار وإدارة الثروة. وفي عالم يزداد تعقيداً، أصبحت القدرة على التنقّل بسلاسة وحرية عبر الحدود واحدة من أقوى الأدوات الاستراتيجية للحفاظ على الثروة وتعزيز نموها.”

من جهتها، قالت Moira Boyle، المديرة التنفيذية الأولى والمسؤولة العالمية عن قطاع السلع الفاخرة في شركة Altrata: “من أبرز النتائج الملفتة في هذا التقرير هو استمرار تنامي الثروة القائمة على ريادة الأعمال على مستوى العالم. إذ تشير المعطيات بأن ما يقرب من 80% من أصحاب الثروات الفائقة المولودين في الخارج هم من العصاميين الذين صنعوا ثرواتهم بأنفسهم، ما يؤكد بأن الابتكار والطموح وريادة الأعمال هي المحركات الرئيسية للثروة الحديثة.”

وأضافت: “في الوقت نفسه، يشهد عدد شريحة الأفراد أصحاب الثروات الفائقة (UHNW) نمواً متسارعاً، ومن المتوقع أن تتضاعف ثرواتهم ونفوذهم بشكل ملحوظ بحلول نهاية العقد. بالتالي، بات من الضروري أن تفهم المؤسسات طبيعة هذه الفئة من الأفراد وكيفية تكوين ثرواتها، من أجل اقتناص الفرص وبناء الشراكات والحفاظ على قدرتها التنافسية في الأسواق سريعة التغير.”

ملاحظات للمحرّرين:

*يُقصد بفئة أصحاب الثروات الفائقة (UHNW) أولئك الأفراد الذين تزيد قيمة صافي ثرواتهم القابلة للاستثمار عن 30 مليون دولار.

**يُطلق وصف “الأثرياء المولودون في الخارج” على الأفراد الذين تتخطى ثرواتهم 30 مليون دولار، والذين ولدوا خارج البلاد التي يقيمون فيها حالياً، والتي تشكّل مركز أعمالهم الأساسي (إن وُجد).

***وفقاً لاستطلاع نفّذته Arton Capital خلال الفترة من 9 إلى 14 يناير 2026، وشمل 1,000 من المقيمين الأثرياء في الولايات المتحدة الأمريكية ممن تتراوح أعمارهم بين 18 و70 عاماً وتجاوزت ثرواتهم مليون دولار، فإن 33% من المشاركين أشاروا إلى أنهم أصبحوا أكثر ميلاً لمغادرة الولايات المتحدة مما كانوا عليه في الفترة التي سبقت الانتخابات الرئاسية لعام 2024.

****يُستخدم مصطلح “المواطنون العالميون” في سياق هذا التقرير كمرادف مباشر للإشارة إلى فئة “الأثرياء المولودين في الخارج.”

يمكن الاطلاع على الصورة المرفقة بهذا البيان الصحفي عبر الرابط الالكتروني التالي: https://www.globenewswire.com/NewsRoom/AttachmentNg/85811040-92fb-42c9-bb5d-92088ad73e53

جهة الاتصال: [email protected]


GLOBENEWSWIRE (Distribution ID 9718538)

Der weltweite Wohlstand macht sich von nationalen Grenzen unabhängig, da mittlerweile jeder fünfte Superreiche im Ausland geboren wurde

  • Die Zahl der Ultra-High-Net-Worth-Personen (UHNW) wird bis 2030 voraussichtlich 734.100 erreichen, was einem Anstieg von 33 % entspricht
  • Das Gesamtvermögen der reichsten Menschen der Welt wird bis 2030 auf 84 Billionen Dollar ansteigen
  • Fast 79 % haben ihr Vermögen selbst erwirtschaftet, während nur 5 % ihr Vermögen ausschließlich geerbt haben

MONTREAL, May 12, 2026 (GLOBE NEWSWIRE) — Der neueste Bericht von Altrata, Global Citizens: Entrepreneurship, Mobility and the Ultra Wealthy, gesponsert von der führenden Beratungsfirma für Investitionsmigration Arton Capital, hat ergeben, dass jeder fünfte der weltweit vermögendsten Privatpersonen (UHNWI*) im Ausland geboren ist**, was den zunehmend internationalen Charakter der heutigen Superreichen verdeutlicht. Der wegweisende Bericht kam zudem zu dem Ergebnis, dass die Zahl der Ultra-Vermögenden bis 2030 um ein Drittel (33 %) auf 734.100 steigen wird.

Die Zahl der Ultra-High-Net-Worth-Personen wird voraussichtlich rasch zunehmen

Der Bericht prognostiziert einen raschen Anstieg des Nettovermögens von vermögenden Privatpersonen weltweit. Ihr gemeinsames Nettovermögen wird voraussichtlich von 63 Billionen Dollar im Jahr 2025 auf 84 Billionen Dollar bis zum Ende des Jahrzehnts ansteigen. Bis zum Jahr 2030 werden schätzungsweise 7,7 Millionen Menschen über ein Vermögen von mehr als 5 Millionen Dollar verfügen.

Vermögensbildung wird von global denkenden Self-Made-Persönlichkeiten geprägt

Bezeichnenderweise zeigt die Untersuchung, dass im Ausland geborene UHNW-Personen überwiegend „Vermögensschöpfer“ und keine Erben sind. Etwa 79 % haben ihr Vermögen selbst erwirtschaftet, während 16 % ihren Wohlstand auf eine Kombination aus unternehmerischem Handeln und Erbschaft zurückführen und nur 5 % ihr Vermögen vollständig geerbt haben.

Die Ergebnisse deuten auf einen strukturellen Wandel in der Art und Weise hin, wie globaler Wohlstand geschaffen und verwaltet wird. Persönliches Vermögen ist zunehmend weniger an einen einzelnen Nationalstaat gebunden, da die reichsten Menschen der Welt ihr Leben, ihr Vermögen und ihre Geschäfte über mehrere Rechtsordnungen hinweg organisieren. Dies spiegelt sich in der Art und Weise wider, wie die heutigen Ultra-High-Net-Worth-Personen weltweit agieren: 17 % besitzen ganz oder teilweise Unternehmen mit Sitz außerhalb ihres Wohnsitzlandes, während 34 % ihre Hochschulausbildung außerhalb ihres Geburtslandes absolviert haben – was deutlich macht, dass grenzüberschreitende Mobilität kein Zufallsprodukt ist, sondern fest in der Art und Weise verankert ist, wie modernes Vermögen aufgebaut wird.

Insgesamt zeigen die Daten einen eindeutigen Zusammenhang zwischen Mobilität und Unternehmertum. International mobile Menschen gründen eher Unternehmen, nutzen Chancen über Grenzen hinweg und schaffen sich ihr eigenes Vermögen – was eine Gruppe widerspiegelt, die sich durch Ehrgeiz, Risikobereitschaft und Zugang zu globalen Märkten auszeichnet. Mobilität ist in diesem Zusammenhang ein entscheidender Faktor für die Schaffung von Wohlstand in der heutigen Zeit.

Ein Leben über Landesgrenzen hinweg wird für die Superreichen zur Normalität

Während Vermögen zunehmend grenzüberschreitend verteilt ist, dominieren wichtige Weltstädte weiterhin als wichtigste Zentren für sehr vermögende Privatpersonen.

London bleibt ein bedeutender Standort für sehr vermögende Privatpersonen, insbesondere aus dem Bank- und Finanzsektor, trotz zunehmender Herausforderungen wie verschärfter Steuerregelungen und Handelsbeschränkungen.

Gleichzeitig behaupten sich die USA weiterhin als weltweit führendes Vermögenszentrum, auf das rund 40 % der globalen UHNW-Bevölkerung (205.000 Personen) entfallen, was ihre anhaltende Attraktivität selbst inmitten sich wandelnder politischer Verhältnisse unterstreicht. Allerdings könnten sich die sich wandelnden politischen Rahmenbedingungen allmählich auf künftige Kapitalbewegungen auswirken, da frühere Untersuchungen von Arton Capital darauf hindeuten, dass ein Drittel der amerikanischen Millionäre*** aufgrund der Auswirkungen von Trumps Präsidentschaft erwägt, die USA zu verlassen.

In der Golfregion festigt Dubai seinen Ruf als „Zentrum für junge Vermögende“ für die globale Elite, wobei fast ein Fünftel (19 %) der im Ausland geborenen UHNW-Personen in der Stadt unter 50 Jahre alt sind. Dieser Umstand unterstreicht – trotz der anhaltenden geopolitischen Spannungen im Nahen Osten – einen allgemeinen Trend: Ultra-High-Net-Worth-Personen ziehen sich nicht aus dem globalen Geschehen zurück, sondern gehen bei der Frage, wie und wo sie ihr Vermögen einsetzen, zunehmend strategisch vor.

Armand Arton, CEO von Arton Capital, erklärte: „Globale Mobilität ist nicht länger ein Nebenprodukt der Vermögensbildung – sie ist ein strategischer Vorteil, der diese untermauert. Die erfolgreichsten Menschen unserer Zeit bauen nicht nur Unternehmen auf – sie schaffen Zugang: zu Märkten, Talenten, Bildung und langfristiger Sicherheit über verschiedene Ländergrenzen hinweg.“

„Was wir beobachten, ist eine Entkopplung von Wohlstand und geografischer Lage. Die erfolgreichsten Personen strukturieren ihr Leben und ihr Vermögen über mehrere Länder hinweg und verringern so ihre Abhängigkeit von einem einzelnen Land. Die nächste Generation der vermögendsten Privatpersonen denkt über Lösungen, die sich auf ein einzelnes Land beschränken, hinaus und legt Wert auf Flexibilität, Widerstandsfähigkeit und Wahlmöglichkeiten hinsichtlich der Art und Weise, wie und wo sie leben, investieren und ihr Vermögen vermehren. In einer immer komplexer werdenden Welt entwickelt sich die Fähigkeit, sich nahtlos über Grenzen hinweg zu bewegen, zu einem der wirksamsten Mittel zur Erhaltung und Schaffung von Wohlstand.“

Moira Boyle, Senior Director und Global Head of Luxury bei Altrata, sagte: „Was bei dieser Untersuchung besonders auffällt, ist der anhaltende Anstieg der unternehmerischen Vermögensbildung auf globaler Ebene. Fast 80 % der im Ausland geborenen Superreichen sind Selfmade-Millionäre, was verdeutlicht, dass der heutige Wohlstand zunehmend von Innovation, Ehrgeiz und dem Aufbau von Unternehmen geprägt ist.“

„Gleichzeitig wächst die Gruppe der Ultra-High-Net-Worth-Individuals (UHNW) rasant, wobei ihr Gesamtvermögen und ihr Einfluss bis zum Ende des Jahrzehnts voraussichtlich erheblich zunehmen werden. Für Unternehmen ist es von entscheidender Bedeutung zu verstehen, wer diese Personen sind und wie ihr Vermögen entsteht, um Chancen zu erkennen, Beziehungen aufzubauen und in einem sich rasch wandelnden Markt wettbewerbsfähig zu bleiben.“

Hinweise für die Redaktion

*Als „Ultra High Net Worth“ gelten Personen mit einem Nettovermögen von mehr als 30 Millionen US-Dollar.

**Als im Ausland geborene Vermögende gelten Personen mit einem Nettovermögen von mehr als 30 Millionen US-Dollar, die außerhalb des Landes geboren wurden, in dem sie derzeit leben und in dem ihr Hauptgeschäftssitz (sofern vorhanden) liegt.

***Zwischen dem 9. Januar 2026 und dem 14. Januar 2026 befragte Arton Capital 1.000 in den USA ansässige Personen im Alter von 18 bis 70 Jahren mit einem Nettovermögen von mindestens 1 Million US-Dollar. 33 % der Befragten gaben an, dass sie eher bereit seien, die USA zu verlassen, als dies vor der Präsidentschaftswahl 2024 der Fall war.

****Der Begriff „Weltbürger“ wird in diesem Bericht synonym mit „im Ausland geborene Vermögende“ verwendet.

Ein Foto zu dieser Mitteilung finden Sie unter https://www.globenewswire.com/NewsRoom/AttachmentNg/85811040-92fb-42c9-bb5d-92088ad73e53


GLOBENEWSWIRE (Distribution ID 9718538)